keyword
MENU ▼
Read by QxMD icon Read
search

Locally advanced pancreatic cancer

keyword
https://www.readbyqxmd.com/read/28643741/prognostic-and-predictive-markers-of-response-to-treatment-in-patients-with-locally-advanced-unresectable-and-metastatic-pancreatic-adenocarcinoma-treated-with-gemcitabine-nab-paclitaxel-results-of-a-retrospective-analysis
#1
Ana Fernández Montes, Paula González Villarroel, Manuel Valladares Ayerbes, Juan De la Cámara Gómez, Guillermo Quintero Aldana, Lidia Vázquez Tuñas, Mercedes Salgado Fernández, Mónica Jorge Fernández
BACKGROUND: Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although insufficient data are available on prognostic and predictive markers of response to treatment. OBJECTIVE: The objective of this study is to identify treatment response markers in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. MATERIALS AND METHODS: This is an observational, retrospective, and multicenter study...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28638216/role-of-surgery-in-pancreatic-cancer
#2
EDITORIAL
Trond A Buanes
Treatment of pancreatic cancer is multimodal and surgery is an essential part, mandatory for curative potential. Also chemotherapy is essential, and serious postoperative complications or rapid disease progression may preclude completion of multimodal treatment. The sequence of treatment interventions has therefore become an important concern, and numerous ongoing randomized controlled trials compare clinical outcome after upfront surgery and neoadjuvant treatment with subsequent resection. In previous years, borderline resectable and locally advanced pancreatic cancer was most often considered unresectable...
June 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28625958/pain-management-of-pancreatic-cancer-patients-with-high-intensity-focused-ultrasound-therapy
#3
Yulan Shi, Xiao Ying, Xiaoye Hu, Hong Shen
This study was performed to evaluate cancer pain control of high-Intensity focused ultrasound ablation (HIFU) and to manage the HIFU treatment pain in advanced pancreatic cancer patients with analgesics. We collected 71 locally advanced pancreatic cancer patients treated with HIFU from 2013 March to 2014 January in our hospital. The cancer pain (pre-HIFU and two weeks after HIFU) and HIFU treatment pain were evaluated respectively. The numeric rating scale (NRS) was used as the tool of pain evaluation. The related factors with pains were analyzed...
January 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28621885/multiagent-induction-chemotherapy-followed-by-chemoradiation-is-associated-with-improved-survival-in-locally-advanced-pancreatic-cancer
#4
Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido-Laguna, George M Cannon
BACKGROUND: The role of chemoradiotherapy (CRT) in locally advanced pancreatic cancer (LAPC) is uncertain after multiple randomized clinical trials have yielded mixed results. The authors used the National Cancer Database (NCDB) to determine whether CRT yields a survival benefit compared with chemotherapy alone (CT). METHODS: Patients with nonmetastatic LAPC diagnosed during 2004 through 2014 were identified in the NCDB. Patients who received CT were compared with those who received CRT using chi-square analysis...
June 16, 2017: Cancer
https://www.readbyqxmd.com/read/28620685/the-efficacy-of-a-new-high-intensity-focused-ultrasound-therapy-for-locally-advanced-pancreatic-cancer
#5
Jing Zhao, Fuguang Zhao, Yulan Shi, Yongchuan Deng, Xiaoye Hu, Hong Shen
PURPOSE: To compare the survival benefit and safety of the low power cumulative and traditional high intensity focused ultrasound (HIFU) for locally advanced pancreatic cancer. METHOD: We retrospectively analyzed 38 patients with locally advanced, inoperable, stage III pancreatic patients received HIFU treatment between January 2008 and April 2014 in the Department of Surgery, the Second Affiliated Hospital, Zhejiang University, School of Medicine. 11 of them received the low power cumulative HIFU treatment, while other 27 received the traditional HIFU treatment...
June 15, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28612201/supportive-care-in-pancreatic-ductal-adenocarcinoma
#6
REVIEW
B Laquente, A Calsina-Berna, A Carmona-Bayonas, P Jiménez-Fonseca, I Peiró, A Carrato
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612015/oligometastatic-disease-in-pancreatic-cancer-how-to-proceed
#7
REVIEW
Bernhard W Renz, Stefan Boeck, Falk Roeder, Christoph Trumm, Volker Heinemann, Jens Werner
BACKGROUND: Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or ablative treatment options for advanced-stage disease. However, highly selected patients suffering from synchronous and metachronous oligometastatic PDAC may potentially benefit from a surgical resection with an acceptable morbidity...
March 2017: Visceral Medicine
https://www.readbyqxmd.com/read/28602054/the-role-of-consolidation-chemo-radiotherapy-in-locally-advanced-pancreatic-cancer-receiving-chemotherapy-an-updated-systematic-review-and-meta-analysis
#8
Jeffrey S Chang, Yen-Feng Chiu, Jih-Chang Yu, Li-Tzong Chen, Hui-Ju Ch'ang
Purpose: The role of consolidation chemoradiation (CCRT) after systemic chemotherapy in locally advanced pancreatic cancer (LAPC) is still controversial. We aim to evaluate the effectiveness of CCRT in LAPC using systematic review and meta-analysis of prospective studies. Materials and Methods: Prospective clinical trials of LAPC receiving chemotherapy with or without subsequent CCRT were included in the analysis. We systematically searched in PubMed, Medline, Embase, Web of Science...
June 9, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28600474/use-of-angiotensin-system-inhibitors-is-associated-with-immune-activation-and-longer-survival-in-non-metastatic-pancreatic-ductal-adenocarcinoma
#9
Hao Liu, Kamila Naxerova, Matthias Pinter, Joao Incio, Hang Lee, Kohei Shigeta, William W Ho, Jonathan A Crain, Alex Jacobson, Theodoros Michelakos, Daniella Dias-Santos, Andrea Zanconato, Theodore S Hong, Jeffrey W Clark, Janet E Murphy, David P Ryan, Vikram Deshpande, Keith D Lillemoe, Carlos Fernandez-Del Castillo, Michael Downes, Ronald M Evans, James Michaelson, Cristina R Ferrone, Yves Boucher, Rakesh K Jain
Angiotensin system inhibitors (ASIs) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients.<br /><br />Experimental Design: We performed an analysis of the records of ASI users and non-user patients with PDAC seen at Massachusetts General Hospital between January 2006 and December 2010. To identify mechanisms of ASIs in PDAC, we performed RNA-Seq of resected primary lesions...
June 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28599404/neoadjuvant-chemotherapy-for-pancreatic-cancer-effects-on-cancer-tissue-and-novel-perspectives
#10
Hidehiro Tajima, Isamu Makino, Yoshinao Ohbatake, Shinichi Nakanuma, Hironori Hayashi, Hisatoshi Nakagawara, Tomoharu Miyashita, Hiroyuki Takamura, Tetsuo Ohta
Chemotherapy for pancreatic cancer has diversified following the addition of more treatment regimens; however, in spite of this, pancreatic cancer remains a fatal disease. Preoperative (neoadjuvant) chemotherapy (NAC) or neoadjuvant chemoradiation therapy (NACRT) has been developed and implemented. For patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), a number of clinical trials have been conducted; NACRT was demonstrated to improve resectability, R0 resection rate, overall survival rate, disease-free survival rate and even an LAPC and BRPC survival advantage over NAC...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28599299/neoadjuvant-radiation-followed-by-resection-versus-upfront-resection-for-locally-advanced-pancreatic-cancer-patients-a-propensity-score-matched-analysis
#11
Xing Chen, Geng Liu, Kaiqiang Wang, Guodong Chen, Jinjin Sun
BACKGROUND AND AIM: To compare cancer-specific survival (CSS) between patients who received neoadjuvant radiation followed by resection (NRR) and those who received upfront resection (UR) for locally advanced pancreatic cancer (LAPC). METHODS: A total of 772 LAPC patients who underwent curative-intent surgical resection with or without neoadjuvant radiation from 2004 to 2013 were identified from the Surveillance, Epidemiology, and End Result (SEER) database. Propensity score matching (PSM) was conducted to eliminate possible bias...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28597040/phase-ii-study-of-induction-gemcitabine-and-s-1-followed-by-chemoradiotherapy-and-systemic-chemotherapy-using-s-1-for-locally-advanced-pancreatic-cancer
#12
Kentaro Sudo, Ryusuke Hara, Kazuyoshi Nakamura, Emiri Kita, Akiko Tsujimoto, Taketo Yamaguchi
PURPOSE: S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS: The treatment consisted of four cycles of induction GS (S-1 60, 80, or 100 mg/day based on body surface area for 14 days every 3 weeks plus GEM 1000 mg/m(2) on days 8 and 15), followed by S-1 (80, 100, or 120 mg/day based on body surface area on days 1-14 and 22-35) and concurrent radiotherapy (50...
June 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28590776/clinical-effects-of-chemoradiotherapy-in-pursuit-of-optimal-treatment-of-locally-advanced-unresectable-pancreatic-cancer
#13
Kenta Sui, Takehiro Okabayashi, Yasuo Shima, Sojiro Morita, Jun Iwata, Tatsuaki Sumiyoshi, Yuichi Saisaka, Yasuhiro Hata, Yoshihiro Noda, Manabu Matsumoto, Akihito Nishioka, Tastuo Iiyama, Yasuhiro Shimada
OBJECTIVES: The treatment of locally advanced unresectable pancreatic cancer remains extremely challenging, particularly as the efficacy of concurrent chemoradiotherapy (CRT) remains unclear. METHODS: We studied 93 patients (8.0%) with locally advanced unresectable pancreatic cancer without distant metastases from among a total group of 1168 patients who were diagnosed with pancreatic cancer from March 2005 to November 2015 at Kochi Health Sciences Center. We therefore evaluated the clinical efficacy of CRT in patients with locally advanced unresectable pancreatic cancer...
June 7, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28588798/combination-therapy-with-gemcitabine-and-nab-paclitaxel-for-locally-advanced-unresectable-pancreatic-cancer
#14
Takeshi Saito, Keinosuke Ishido, Daisuke Kudo, Norihisa Kimura, Taiichi Wakiya, Yoshihito Nakayama, Kenichi Hakamada
The aim of the present study was to investigate the early treatment outcomes of combined gemcitabine and nab-paclitaxel treatment for locally advanced unresectable pancreatic cancer (LURPC). The subjects comprised 7 patients with LURPC receiving the abovementioned combination therapy at the Hirosaki University Hospital (Hirosaki, Japan) between January and September, 2015. The clinicopathological factors, adverse events and response to treatment were investigated. To determine whether the cases were unresectable, the National Comprehensive Cancer Network guidelines, version 2...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28588736/treatment-outcomes-of-concurrent-hyperthermia-and-chemoradiotherapy-for-pancreatic-cancer-insights-into-the-significance-of-hyperthermia-treatment
#15
Toshiya Maebayashi, Naoya Ishibashi, Takuya Aizawa, Masakuni Sakaguchi, Tsutomu Sato, Jiro Kawamori, Yoshiaki Tanaka
Patients with locally advanced unresectable pancreatic cancer (LAUPC) have a poor prognosis. In addition their quality of life impaired by cancer pain and biliary tract infections. Therefore, multimodality therapy and selection of optimal treatment methods are essential for achieving prolonged survival. The present study investigated the significance of using hyperthermia concurrently with multimodality therapy to improve treatment outcomes in patients with LAUPC. In total, 13 patients receiving concurrent hyperthermia and chemoradiotherapy (HCR) or chemoradiotherapy (CR) alone for LAUPC between 2002 and 2013 were analyzed retrospectively...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28585779/the-impact-of-initial-cancer-stage-on-the-incidence-of-venous-thromboembolism-the-scandinavian-thrombosis-and-cancer-stac-cohort
#16
I L Gade, S K Braekkan, I A Naess, J-B Hansenx, S C Cannegieter, K Overvad, H Jensvoll, J Hammerstrøm, K Blix, A Tjønneland, S R Kristensen, M T Severinsen
BACKGROUND: Absolute measures of the impact of cancer stage on the incidence of venous thromboembolism (VTE) in distinct cancer types have not been investigated in a large population based cohort study. OBJECTIVES: To investigate differences in incidence rates of objectively confirmed VTE according to development of cancer in a large population based cohort study. Cancer type and stage at the time of diagnosis was taken into account. PATIENTS AND METHODS: The Scandinavian Thrombosis and Cancer cohort includes data regarding cancer types, stages and objectively confirmed VTE diagnoses among 144,952 participants followed from 1993 through 2012...
June 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28569190/single-cell-mrna-profiling-reveals-transcriptional-heterogeneity-among-pancreatic-circulating-tumour-cells
#17
Morten Lapin, Kjersti Tjensvoll, Satu Oltedal, Milind Javle, Rune Smaaland, Bjørnar Gilje, Oddmund Nordgård
BACKGROUND: Single-cell mRNA profiling of circulating tumour cells may contribute to a better understanding of the biology of these cells and their role in the metastatic process. In addition, such analyses may reveal new knowledge about the mechanisms underlying chemotherapy resistance and tumour progression in patients with cancer. METHODS: Single circulating tumour cells were isolated from patients with locally advanced or metastatic pancreatic cancer with immuno-magnetic depletion and immuno-fluorescence microscopy...
May 31, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28566532/risk-and-protective-factors-for-the-occurrence-of-sporadic-pancreatic-endocrine-neoplasms
#18
Roberto Valente, Alastair J Hayes, Sven-Petter Haugvik, Per Hedenström, Darko Siuka, Emilie Korsæth, Daniel Kaemmerer, Stuart Michael Robinson, Patrick Maisonneuve, Gianfranco Delle Fave, Bjorn Lindkvist, Gabriele Capurso
Pancreatic neuroendocrine neoplasms (PNENs) represent 10% of all pancreatic tumors by prevalence. Their incidence has reportedly increased over recent decades in parallel with that of pancreatic adenocarcinoma. PNENs are relatively rare and of the few institutions that have published potential risk factors, findings have been heterogenous. AIM: To investigate the association between potential risk and protective factors for the occurrence of sporadic PNENs across a European population from several institutions...
May 31, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28565894/contemporary-strategies-to-improve-the-outcome-in-locally-advanced-pancreatic-cancer
#19
Rick Schneider, Christoph Späth, Ulrich Nitsche, Mert Erkan, Jörg Kleeff
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an overall 5-year survival rate of less than 7%. After many years of basic and clinical research efforts, pancreatic cancer patients presenting with locally advanced, unresectable tumors remain a therapeutic challenge. Despite the lack of high quality randomized controlled trials, perioperative/ neoadjuvant treatment strategies seem to be beneficial in these patients. At present the FOLFIRINOX regimen, which was established in the palliative setting, is increasingly recognized as the backbone of neoadjuvant therapy for locally advanced PDAC...
May 30, 2017: Minerva Chirurgica
https://www.readbyqxmd.com/read/28560601/induction-chemotherapy-followed-by-resection-or-irreversible-electroporation-in-locally-advanced-pancreatic-cancer-impala-a-prospective-cohort-study
#20
Jantien A Vogel, Steffi J Rombouts, Thijs de Rooij, Otto M van Delden, Marcel G Dijkgraaf, Thomas M van Gulik, Jeanin E van Hooft, Hanneke W van Laarhoven, Robert C Martin, Annuska Schoorlemmer, Johanna W Wilmink, Krijn P van Lienden, Olivier R Busch, Marc G Besselink
BACKGROUND: Following induction chemotherapy, both resection or irreversible electroporation (IRE) may further improve survival in patients with locally advanced pancreatic cancer (LAPC). However, prospective studies combining these strategies are currently lacking, and available studies only report on subgroups that completed treatment. This study aimed to determine the applicability and outcomes of resection and IRE in patients with nonprogressive LAPC after induction chemotherapy. METHODS: This was a prospective, single-center cohort study in consecutive patients with LAPC (September 2013 to March 2015)...
May 30, 2017: Annals of Surgical Oncology
keyword
keyword
110723
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"